Hanna L Kleiboeker

11PUBLICATIONS
6CO-AUTHORS
Nanotoxicology, health and safetyGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Major global burdens of diseaseApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 16, 2026
Beyond Thresholds: CMV Replication Kinetics as Early Predictors of Clinical Risk in Transplant Recipients.

Hanna L Kleiboeker, Jillian L Descourouez, Chris Saddler

|Dec 18, 2025
De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care.

Hanna L Kleiboeker, Margaret R Jorgenson, Michael J Scolarici

|Nov 27, 2024
Impact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients.

Hanna L Kleiboeker, Alyson Prom, Krista Paplaczyk

|Jul 09, 2024
Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients.

Hanna L Kleiboeker, Jacob Wang, Nicole Borkowski

|Dec 11, 2023
Incidence and outcomes of fever of unknown origin after kidney transplant in the modern era.

Margaret R Jorgenson, Sandesh Parajuli, Hanna L Kleiboeker

|Nov 23, 2023
A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience.

Hanna L Kleiboeker, Alyson Prom, Krista Paplaczyk

Pageof 2

Frequent Collaborators

5 joint publications

Margaret R Jorgenson

2 joint publications

Jeannina A Smith

2 joint publications

Didier Mandlebrot

2 joint publications

Krista Paplaczyk